Scholar Rock Holding Corporation Q3 2026 Earnings Recap

Scholar Rock shares fell 6.9% after earnings, with investors likely focused on the slow path from early ISEMBYLD demand to revenue: payer access is lagging enrollment, and the company expects most patients enrolled through October to begin infusions in 2027. The launch is only in its early weeks, but the timing underscores a gap between patient interest and treatment starts.

Key Takeaways

• ISEMBYLD was approved in mid-September for patients with SMA aged 2 and older who are receiving an SMN2-targeted treatment; Scholar Rock began its U.S. launch immediately.
• Through the end of October, patients were enrolling steadily in Scholar Rock Supports across geographies, age groups and background therapies. More than one-third of the top 140 SMA treatment centers had enrolled initial patients, with additional enrollment from other centers.
• Demand is outpacing reimbursement and access. The company cited common early denials and delays, and an anticipated 60–90 days or longer from prescription to infusion; it expects most patients enrolled through October to start infusions in 2027.
• In the Phase III SAPPHIRE study, the recommended dose produced a 2.2-point improvement in motor function versus SMN2-targeted therapy alone, measured by the Hammersmith Functional Motor Scale.
• Scholar Rock resubmitted its European application, expecting a CHMP opinion in the first half of 2027, and submitted its Japan application under priority review. It also agreed to sell its priority review voucher for $205 million.